Trial Profile
AN OPEN-LABEL, MULTICENTER, MULTIPLE-DOSE PHARMACOKINETIC, SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXPERIENCED CCR5-TROPIC HIV-1 INFECTED CHILDREN 2 - <18 YEARS OF AGE
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer; ViiV Healthcare
- 10 Jun 2019 Planned End Date changed from 29 Jul 2019 to 30 Jun 2023.
- 19 Mar 2019 Planned End Date changed from 23 Jan 2023 to 29 Jul 2019.
- 22 Feb 2019 Planned End Date changed from 29 Jul 2019 to 23 Jan 2023.